MedTrace Logo

STIP: Statin Trial for Influenza Patients

NCT00970606 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2017-03-22

Study results available
· View outcomes & findings →

Summary

To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.

Conditions

  • Acute Respiratory Distress Syndrome
  • Influenza
  • H1N1 Influenza

Interventions

DRUG

Rosuvastatin (crestor)

20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge

DRUG

Placebo

Placebo tablet identical to active therapy. 1 tablet per day

Sponsors & Collaborators

  • Gordon Bernard

    lead OTHER

Principal Investigators

  • Gordon R Bernard, M.D. · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970606 on ClinicalTrials.gov